Tag: Enhertu
US FDA Approves Trastuzumab Deruxtecan for the treatment of HER2-Mutant NSCLC
The United States Food and Drug Administration (FDA) has approved trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with...
Trastuzumab deruxtecan Doubles Progression-Free Survival in Metastatic Breast Cancer with Low...
The use of trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival (PFS) compared to standard-of-care treatment with...
FDA Approves Trastuzumab Deruxtecan for Adult Patients with Unresectable or Metastatic...
The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with unresectable or metastatic HER2...
The Rise of HER2-targeting ADCs and the Journey from Breakthrough Therapy...
Antibody-drug conjugates (ADCs) as precision targeted cancer therapies have started to deliver on their early promise as an innovative novel drug modality as demonstrated...
World ADC London 2022: What to Expect
With World ADC London staring later this week, excitement is building for the first in-person event in two years, with virtual attendance options available! With 70+ speakers...
Trastuzumab Deruxtecan Receives Breakthrough Therapy Designation for HER2+ Metastatic Breast Cancer...
The U.S. Food and Drug Administration (FDA) has granted trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca), a HER2 directed antibody-drug conjugate (ADC), Breakthrough Therapy...
Remegen’s Disitamab Vedotin Attracts China’s largest-ever out-license Agreement at US $...
Earlier this month, Remegen Biosciences, a Shandong-based biotech company operating since 2008, scored the largest ever out-license deal for a Chinese biotech company when...
First patient Dosed with Trastuzumab Deruxtecan in DESTINY-Breast09 Head-to-Head HER2+ mBC...
A first patient was dosed in DESTINY-Breast09 (NCT04784715), a global head-to-head Phase 3 clinical trial evaluating the safety and efficacy of trastuzumab deruxtecan (Enhertu®;...
Daiichi Sankyo Reaffirms Long-term Goals with Increased Investment in ADCs
With the launch of fam-trastuzumab-deruxtecan-nxki (Enhertu®), Daiichi Sankyo's first antibody-drug conjugates, coupled with a strong pipeline of innovative ADC, the company has established a...
Daiichi Sankyo: Realigning for Agility
Daiichi Sankyo first approached me in 2015 with a potential opportunity in global oncology development, and I listened carefully as they explained how they...
